Already back to 1988, Mintun et al. [25] pioneered in vivo molecular imaging of breast cancer with PET using the estrogen receptor ligand 16α-[18F]-fluoro-17β-estradiol (18F-FES) in a set of 13 patients with primary breast tumours. Here, ESR1 is linked to breast carcinoma.